info@renovatherapeutics.com
Participate in the AC6 study
Meet The Team.
-
Jack W. Reich, Ph.D. President and Chief Executive Officer
Jack W. Reich, Ph.D. has played an important role in the development of the biotech industry in San Diego. He has been a pioneer, not only in the local industry since 1987, when he became a founding officer of Gensia, but most especially in the field of gene therapy.
Understanding congestiveHeart Failure.
-
Using gene therapy to treat disease was first theorized in the 1970's. However, it wasn't until 1990 that the first approved gene therapy was performed at the National Institutes of Health™ Clinical Center in Bethesda, Maryland. The patient was a four-year old child who was born with a rare genetic disease called Severe Combined Immunodeficiency (SCID) which prevented his body from producing a crucial enzyme, adenosine deaminase (ADA).
News.
-
Clinical Trial of AC6 Gene Therapy for Heart Failure - Current Status
Dr. Hammond's research has focused on developing a gene therapy congestive heart failure by increasing the heart's ability to pump blood to meet the body's needs.
Normal hearts respond to catecholamines (the "flight and fright" hormones) by increasing the pumping strength and rate and the cardiac output goes up.